Cargando…

Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017–2020

BACKGROUND: Statins remain the backbone of lipid management. Nevertheless, the degree to which statins can be used and dosed in clinical practice remains a great challenge, also due to statin intolerance (SI). The lack of widely accepted SI definition leads to poor understanding of the condition and...

Descripción completa

Detalles Bibliográficos
Autores principales: Parhofer, K G, Anastassopoulou, A, Calver, H, Becker, C, Singh Rathore, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779769/
http://dx.doi.org/10.1093/ehjdh/ztac076.2789
_version_ 1784856690851577856
author Parhofer, K G
Anastassopoulou, A
Calver, H
Becker, C
Singh Rathore, A
author_facet Parhofer, K G
Anastassopoulou, A
Calver, H
Becker, C
Singh Rathore, A
author_sort Parhofer, K G
collection PubMed
description BACKGROUND: Statins remain the backbone of lipid management. Nevertheless, the degree to which statins can be used and dosed in clinical practice remains a great challenge, also due to statin intolerance (SI). The lack of widely accepted SI definition leads to poor understanding of the condition and SI patient profile PURPOSE: To estimate the current SI prevalence and understand better the patient characteristics, using machine learning techniques METHODS: Retrospective cohort study, based on representative sample of electronic patient records from outpatient setting in Germany. Patients were included if they had high CV risk, atherosclerotic cardiovascular disease (ASCVD) or hypercholesterolemia (HC), between 2017 and 2020. Patients were categorized as having “absolute” (history of SI events and permanent statin discontinuation) or “partial” (history of SI events while treated with statins) SI. Machine learning techniques were utilized to calibrate the prevalence estimates and to identify patient clusters. Estimates of SI prevalence were derived based on different rules and confidence levels (high, moderate and low). The low confidence estimates contain the most uncertainty in identifying SI RESULTS: The study population consisted of 292,603 patients (57.3% aged >70 years; 55.6% male). Of these, ∼24% had high CV risk, ∼56% had ASCVD, and ∼20% had HC. After deploying machine learning, the SI identification improved by ∼27% in absolute SI and by ∼57% in partial SI patients, resulting in a maximum estimate of 12.5% SI with high/moderate confidence and further 11.8% with low confidence (absolute SI 15.8%, partial SI 8.5%). The low confidence group may contain patients with insufficient statin treatment due to reasons other than SI (e.g. clinical inertia). Statistically significant risk factors for SI were hypothyroidism, vitamin D deficiency, liver and chronic kidney disease. Cramps, muscle spasms, myalgia and myopathy were the most common statin associated muscle symptoms (SAMS) observed in the SI population. Atorvastatin 40mg was the most frequently down-titrated statin, while simvastatin to atorvastatin was the most predominant class switch in SI patients. Machine learning techniques applied on high confidence SI patients characteristics and the most commonly observed cluster for patients over 60 years showed predominant musculoskeletal disorders, concomitant high SAMS incidence and high use of multiple statins. In males under 60 years, depression and somatoform disorders along with musculoskeletal disorders, pain, and gastric events were common, while females under 60 years had predominant depressive episodes, along with musculoskeletal, mental, and metabolic disorders CONCLUSION: Addressing the complexity in defining SI using advanced analytics, this study provides prevalence estimates and describes distinct patients clusters that may inform diagnosis and optimal treatment pathways for SI patients in Germany FUNDING ACKNOWLEDGEMENT: Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo Europe GmbH
format Online
Article
Text
id pubmed-9779769
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97797692023-01-27 Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017–2020 Parhofer, K G Anastassopoulou, A Calver, H Becker, C Singh Rathore, A Eur Heart J Digit Health Abstracts BACKGROUND: Statins remain the backbone of lipid management. Nevertheless, the degree to which statins can be used and dosed in clinical practice remains a great challenge, also due to statin intolerance (SI). The lack of widely accepted SI definition leads to poor understanding of the condition and SI patient profile PURPOSE: To estimate the current SI prevalence and understand better the patient characteristics, using machine learning techniques METHODS: Retrospective cohort study, based on representative sample of electronic patient records from outpatient setting in Germany. Patients were included if they had high CV risk, atherosclerotic cardiovascular disease (ASCVD) or hypercholesterolemia (HC), between 2017 and 2020. Patients were categorized as having “absolute” (history of SI events and permanent statin discontinuation) or “partial” (history of SI events while treated with statins) SI. Machine learning techniques were utilized to calibrate the prevalence estimates and to identify patient clusters. Estimates of SI prevalence were derived based on different rules and confidence levels (high, moderate and low). The low confidence estimates contain the most uncertainty in identifying SI RESULTS: The study population consisted of 292,603 patients (57.3% aged >70 years; 55.6% male). Of these, ∼24% had high CV risk, ∼56% had ASCVD, and ∼20% had HC. After deploying machine learning, the SI identification improved by ∼27% in absolute SI and by ∼57% in partial SI patients, resulting in a maximum estimate of 12.5% SI with high/moderate confidence and further 11.8% with low confidence (absolute SI 15.8%, partial SI 8.5%). The low confidence group may contain patients with insufficient statin treatment due to reasons other than SI (e.g. clinical inertia). Statistically significant risk factors for SI were hypothyroidism, vitamin D deficiency, liver and chronic kidney disease. Cramps, muscle spasms, myalgia and myopathy were the most common statin associated muscle symptoms (SAMS) observed in the SI population. Atorvastatin 40mg was the most frequently down-titrated statin, while simvastatin to atorvastatin was the most predominant class switch in SI patients. Machine learning techniques applied on high confidence SI patients characteristics and the most commonly observed cluster for patients over 60 years showed predominant musculoskeletal disorders, concomitant high SAMS incidence and high use of multiple statins. In males under 60 years, depression and somatoform disorders along with musculoskeletal disorders, pain, and gastric events were common, while females under 60 years had predominant depressive episodes, along with musculoskeletal, mental, and metabolic disorders CONCLUSION: Addressing the complexity in defining SI using advanced analytics, this study provides prevalence estimates and describes distinct patients clusters that may inform diagnosis and optimal treatment pathways for SI patients in Germany FUNDING ACKNOWLEDGEMENT: Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo Europe GmbH Oxford University Press 2022-12-22 /pmc/articles/PMC9779769/ http://dx.doi.org/10.1093/ehjdh/ztac076.2789 Text en Reproduced from: European Heart Journal, Volume 43, Issue Supplement_2, October 2022, ehac544.2789, https://doi.org/10.1093/eurheartj/ehac544.2789 by permission of Oxford University Press on behalf of the European Society of Cardiology. The opinions expressed in the Journal item reproduced as this reprint are those of the authors and contributors, and do not necessarily reflect those of the European Society of Cardiology, the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated. The mention of trade names, commercial products or organizations, and the inclusion of advertisements in this reprint do not imply endorsement by the Journal, the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated. The editors and publishers have taken all reasonable precautions to verify drug names and doses, the results of experimental work and clinical findings published in the Journal. The ultimate responsibility for the use and dosage of drugs mentioned in this reprint and in interpretation of published material lies with the medical practitioner, and the editors and publisher cannot accept liability for damages arising from any error or omissions in the Journal or in this reprint. Please inform the editors of any errors. © The Author(s) 2022. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Parhofer, K G
Anastassopoulou, A
Calver, H
Becker, C
Singh Rathore, A
Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017–2020
title Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017–2020
title_full Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017–2020
title_fullStr Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017–2020
title_full_unstemmed Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017–2020
title_short Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017–2020
title_sort estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in germany between 2017–2020
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779769/
http://dx.doi.org/10.1093/ehjdh/ztac076.2789
work_keys_str_mv AT parhoferkg estimatingprevalenceandcharacteristicsofstatinintoleranceamonghighandveryhighcardiovascularriskpatientsingermanybetween20172020
AT anastassopouloua estimatingprevalenceandcharacteristicsofstatinintoleranceamonghighandveryhighcardiovascularriskpatientsingermanybetween20172020
AT calverh estimatingprevalenceandcharacteristicsofstatinintoleranceamonghighandveryhighcardiovascularriskpatientsingermanybetween20172020
AT beckerc estimatingprevalenceandcharacteristicsofstatinintoleranceamonghighandveryhighcardiovascularriskpatientsingermanybetween20172020
AT singhrathorea estimatingprevalenceandcharacteristicsofstatinintoleranceamonghighandveryhighcardiovascularriskpatientsingermanybetween20172020